OUR SPONSORS

The Intl. Lung Cancer Summit 2024 is supported by our partners, with no influence on the content:

for sponsoring opportunities, please contact us at sponsoring@lungcancersummit.org

SAVE THE DATE

5 SGMO CME Credits

An application has been made to the UEMS EACCME® for CME accreditation of this event

Add this to your calendar

This meeting is accredited and CME-certified! Add this event to your calendar by selecting your calendar and download your certificate of attendance after the conference.

Swiss Society of Medical Oncology: 5 credit points

Tentative PROGRAM

4th October 2024

All times are in Central European Time

10.00

Welcome by Chairs

Solange Peters & Alfredo Addeo

10.00

Advancements in Lung Cancer Diagnostics: Current Guidelines and Emerging Tests

tbd

10.30

Novel Therapeutic Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

Anne-Marie Dingemans (Netherlands)

10.50

Rare But Actionable: How To Target for RET, METex14 and NTRK

Roberto Ferrara (Italy)

11.20

Open Discussion & Coffee Break

11.30

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

Biagio Ricciuti (USA)

12.00

The Emerging Role of ADCs in Lung Cancer: Navigating Timing and Applications for Optimal Use

Jarushka Naidoo (Ireland)

13.30

Surgical Dilemmas in NSCLC: Defining Resectability for Optimal Patient Outcomes in the IO Era

Nuria maria novoa (spain)

14.00

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

Delvys Rodriguez Abreu (Spain)

15.00

Open Discussion & Coffee Break

15.20

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

  • We Must Seize Every Opportunity To Cease IO

    Giannis Mountzios (Greece)

  • We Must Maximize IO Benefits Through Prolonged Therapy

    Sandip Patel (USA)

15.50

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

Stephen Liu (USA)

16.15

Open Questions, Patient Cases & Guidelines

Panel Discussion With All